Fortrea (FTRE) Q1 2026 earnings review
Margin Expansion Shines While Revenue Growth Continues to Lag
Fortrea delivered a structurally improving but mixed Q1 2026. Management's relentless focus on cost-cutting is visibly paying off—Adjusted EBITDA surged 55% YoY to $47.0 million, expanding margins despite a shrinking top line. The commercial engine has stabilized, posting a 1.15x book-to-bill ratio (its third straight quarter above 1.1x). However, the top-line story remains a significant drag: revenue fell 2.3% YoY to $636.5 million. Backlog is growing, but it is converting to revenue at a frustratingly slow pace. Full-year guidance implies a continued revenue contraction but meaningful profit growth, setting 2026 up as a year of margin recovery rather than top-line expansion.
🐂 Bull Case
The Q1 book-to-bill ratio of 1.15x marks three consecutive quarters of strong >1.1x bookings, bringing the trailing-12-month ratio to 1.05x. The strategy to win back biotech and pharma clients is gaining traction.
A 55% YoY increase in Adjusted EBITDA on lower revenue is a massive validation of the ongoing cost-reduction programs. Management is successfully defending the bottom line.
🐻 Bear Case
Sales declined 2.3% YoY to $636.5 million. Headwinds from pass-through volatility and weakness in the FSP business continue to mute top-line performance, offsetting the strong bookings.
While vastly improved from a year ago (-$124.2M), operating cash flow in Q1 was still negative at -$17.0M. The company needs to prove it can generate consistent cash flow year-round.
⚖️ Verdict: ⚪
Neutral. The aggressive cost cuts have effectively put a floor under the earnings profile, but an investment in a CRO is fundamentally an investment in backlog conversion. Until top-line revenue stops shrinking, Fortrea remains a 'show-me' restructuring story.
Key Themes
Sustained Commercial Traction
After a disastrous 25Q2 (0.79x book-to-bill), the commercial reset is clearly working. Fortrea printed a 1.15x book-to-bill ratio in Q1 2026, building on 1.14x in 25Q4 and 1.13x in 25Q3. The company is successfully executing its '3 Rs' framework (Reach, Relevance, Repeat), expanding its backlog to an impressive $7.85 billion.
Cost Cutting Drives Massive EBITDA Expansion
Management's primary margin lever—cost reduction—is bearing fruit. SG&A costs (exclusive of D&A) plummeted roughly 17.5% YoY from $121.8M to $100.5M. This disciplined execution allowed Adjusted EBITDA to surge from $30.3M to $47.0M, increasing the margin from 4.6% to 7.4% despite the top-line revenue decline.
Product Innovation: Fortrea Intelligent Technology
Management highlighted the recent launch of 'Fortrea Intelligent Technology' (FIT). This follows previous narratives around their 'Accelerate' platform and positions AI as a force multiplier for feasibility, monitoring, and CRA productivity. By integrating outcomes-based innovation into the R&D ecosystem, Fortrea aims to offset pricing pressure through higher internal efficiency.
The Contradiction: Growing Backlog, Shrinking Revenue
A massive red flag in the CRO model is when backlog grows but revenue shrinks. Backlog grew to $7.85B, yet revenue fell 2.3% YoY. This contradicts the narrative of a robust turnaround and suggests a painfully slow burn rate. Management previously blamed a high mix of slower-burning oncology trials and legacy FSP headwinds; if this structural mix issue isn't resolved, it will cap near-term growth.
Operating Cash Flow Remains Negative in Q1
Fortrea burned $17.0 million in operating cash this quarter. While this is a spectacular improvement from the $124.2 million burned in Q1 2025 (which was marred by an ERP transition), turning structurally cash-flow positive remains a hurdle. Free Cash Flow for the quarter stood at -$25.0 million, highlighting that working capital seasonality is still pressuring the balance sheet in the first half of the year.
Macro: The Uneven Biotech Recovery
Management had guided for an 'uneven' 1H 2026, and the 2.3% revenue contraction confirms the cautious macro backdrop. Biotech clients are taking longer to finalize awards, and weaker bookings from the first half of 2025 are currently burning through the system. Until the macro funding environment accelerates, Fortrea will rely strictly on internal efficiency rather than market tailwinds to drive EPS.
Other KPIs
A dramatic turnaround from $1.9 million in Q1 2025. Adjusted diluted EPS jumped to $0.16 (vs $0.02 last year). This proves that the core operations—once stripped of massive impairment charges and one-time spin costs—are functionally profitable and scaling effectively on the bottom line.
While still a loss, this is a night-and-day comparison versus the $(562.9) million loss recorded in Q1 2025 (which included a massive $488.8M goodwill impairment). The stabilization of the asset base indicates the worst of the spin-off transition pain is firmly in the rearview mirror.
Guidance
Decelerating. Reaffirmed guidance. The midpoint ($2.60B) implies a roughly 4.5% year-over-year contraction from FY25's $2.72 billion. This cements the narrative that 2026 is a transition/rebuilding year focused entirely on margin structure rather than top-line scale.
Accelerating. Reaffirmed guidance. The midpoint ($205M) implies an approximate 8% growth compared to FY25's $189.9 million. Hitting this target will depend almost entirely on maintaining the strict SG&A discipline demonstrated in Q1.
Key Questions
Backlog Conversion Rate
With three straight quarters of >1.1x book-to-bill and a backlog nearing $7.9 billion, why is revenue still shrinking? How much of the backlog consists of slower-burning trials, and when do you expect the burn rate to normalize?
FSP Business Trajectory
You previously cited the FSP (Functional Service Provider) business as a margin and revenue drag. Has the dedicated sales team stopped the bleeding in this unit, or should we model for continued FSP headwinds through the end of 2026?
Path to Cash Generation
Q1 OCF was -$17M. Given the seasonality of your working capital, what is the exact cadence expected to achieve positive Free Cash Flow for the full year 2026, and how much leeway does this leave for further debt paydown?